LITE STRATEGY INC (LITS) Stock Price, Forecast & Analysis
USA - NASDAQ:LITS - US55279B3015 - Common Stock
LITS Key Statistics, Chart & Performance
The current stock price of LITS is 2.1 USD. In the past month the price decreased by -14.98%.
LITS Latest News, Press Relases and Analysis
LITS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About LITS
Company Profile
Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2003-12-18. The firm accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. The company is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.
Company Info
LITE STRATEGY INC
9920 Pacific Heights Blvd, Suite 150
San Diego CALIFORNIA US
Employees: 4
Phone: 18583697100
LITE STRATEGY INC / LITS FAQ
What does LITE STRATEGY INC do?
Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2003-12-18. The firm accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. The company is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.
What is the current price of LITS stock?
The current stock price of LITS is 2.1 USD. The price increased by 14.13% in the last trading session.
What is the dividend status of LITE STRATEGY INC?
LITS does not pay a dividend.
What is the ChartMill technical and fundamental rating of LITS stock?
LITS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists LITS stock?
LITS stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for LITE STRATEGY INC?
LITE STRATEGY INC (LITS) operates in the Health Care sector and the Biotechnology industry.
Should I buy LITS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LITS.
LITS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to LITS.
LITS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LITS. No worries on liquidiy or solvency for LITS as it has an excellent financial health rating, but there are worries on the profitability.
LITS Financial Highlights
Over the last trailing twelve months LITS reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS decreased by -189.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.2% | ||
| ROE | -94.18% | ||
| Debt/Equity | 0 |